InMode Ltd. (NASDAQ:INMD) Given Consensus Recommendation of “Hold” by Brokerages

Shares of InMode Ltd. (NASDAQ:INMD) have been assigned an average recommendation of “Hold” from the nine brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $16.60.

A number of research analysts have weighed in on INMD shares. Needham & Company LLC reiterated a “hold” rating on shares of InMode in a research report on Friday, October 10th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of InMode in a research note on Thursday, January 22nd. UBS Group reduced their price objective on shares of InMode from $16.25 to $16.00 and set a “neutral” rating on the stock in a research report on Thursday, November 6th. BTIG Research restated a “neutral” rating on shares of InMode in a research report on Monday. Finally, Wall Street Zen downgraded InMode from a “buy” rating to a “hold” rating in a report on Saturday, November 8th.

Institutional Trading of InMode

Hedge funds and other institutional investors have recently bought and sold shares of the business. ARGA Investment Management LP increased its stake in InMode by 355.0% in the 3rd quarter. ARGA Investment Management LP now owns 143,658 shares of the healthcare company’s stock worth $2,141,000 after buying an additional 112,087 shares during the period. Divisadero Street Capital Management LP bought a new position in InMode in the 2nd quarter worth about $1,397,000. OMERS ADMINISTRATION Corp increased its position in shares of InMode by 55.3% during the second quarter. OMERS ADMINISTRATION Corp now owns 200,043 shares of the healthcare company’s stock worth $2,889,000 after acquiring an additional 71,231 shares during the period. Squarepoint Ops LLC increased its position in shares of InMode by 92.9% during the second quarter. Squarepoint Ops LLC now owns 143,758 shares of the healthcare company’s stock worth $2,076,000 after acquiring an additional 69,239 shares during the period. Finally, Lind Value II ApS bought a new stake in shares of InMode during the second quarter valued at approximately $3,930,000. Hedge funds and other institutional investors own 68.04% of the company’s stock.

InMode Stock Performance

NASDAQ INMD opened at $15.25 on Wednesday. The business’s 50 day moving average price is $14.40 and its 200-day moving average price is $14.62. InMode has a fifty-two week low of $13.14 and a fifty-two week high of $19.78. The company has a market cap of $963.95 million, a P/E ratio of 7.06 and a beta of 2.13.

InMode Company Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.